Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruggero Moro

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Melanoma Research|June 16, 2026
Melanocortin-1 receptor variants and telomerase reverse transcriptase promoter mutations as prognostic biomarkers in stage IIB-IIC melanomaMarcella Scala, David Lorente-Estellés, Luigi Liguori, et al.
International Wound Journal|June 8, 2018
Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre studyPaola Monari, Ruggero Moro, Alberico Motolese, et al.
Dermatology and Therapy|June 15, 2020
Intralesional Methotrexate for the Treatment of Advanced Keratinocytic Tumors: A Multi-Center Retrospective StudyGiulio Gualdi, Simone Caravello, Fabiano Frasci, et al.
The Oncologist|December 21, 2023
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?Salvatore Alfieri, Rebecca Romanò, Sara Marceglia, et al.
International Journal of Dermatology|April 12, 2026
Improving Risk Stratification for SLNB in Elderly Patients With Melanoma: The SENTINOLD NomogramNieves Martínez Campayo, Sabela Paradela de la Morena, Sebastian Podlipnik, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Melanoma Research|June 16, 2026
Melanocortin-1 receptor variants and telomerase reverse transcriptase promoter mutations as prognostic biomarkers in stage IIB-IIC melanomaMarcella Scala, David Lorente-Estellés, Luigi Liguori, et al.
International Wound Journal|June 8, 2018
Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre studyPaola Monari, Ruggero Moro, Alberico Motolese, et al.
Dermatology and Therapy|June 15, 2020
Intralesional Methotrexate for the Treatment of Advanced Keratinocytic Tumors: A Multi-Center Retrospective StudyGiulio Gualdi, Simone Caravello, Fabiano Frasci, et al.
The Oncologist|December 21, 2023
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?Salvatore Alfieri, Rebecca Romanò, Sara Marceglia, et al.
International Journal of Dermatology|April 12, 2026
Improving Risk Stratification for SLNB in Elderly Patients With Melanoma: The SENTINOLD NomogramNieves Martínez Campayo, Sabela Paradela de la Morena, Sebastian Podlipnik, et al.
Pageof 3